Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
Vestal Point Capital, LP
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$3.6B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
90
positionsALL retained default holdings for this (filer, period), including NULL-value ones
37
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
23
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
Revolution Medicines Inc COMposition key pos:15541 · issuer key iss:1842 | add | +$207M | +2,080,000 | $23.5M | $231M | 295,000 | 2,375,000 | |
BioMarin Pharmaceutical Inc COMposition key pos:11882 · issuer key iss:375 | add | +$23.7M | +575,000 | $178M | $202M | 3,000,000 | 3,575,000 | |
Abivax SA SPONSORED ADSposition key pos:13227 · issuer key iss:50 | trim | −$89.2M | −400,000 | $256M | $167M | 1,900,000 | 1,500,000 | |
Neurocrine Biosciences Inc COMposition key pos:12315 · issuer key iss:1552 | new | +$165M | +1,250,000 | $0 | $165M | — | 1,250,000 | |
Arrowhead Pharmaceuticals Inc COMposition key pos:16618 · issuer key iss:249 | add | +$82.9M | +1,375,000 | $59.8M | $143M | 900,000 | 2,275,000 | |
Enliven Therapeutics Inc COMposition key sid:sec:prov:bf437640b37b30ed62d091e5e9de5808 · issuer key cusip6:29337E | trim | +$68.4M | −580,000 | $59.0M | $127M | 3,830,000 | 3,250,000 | |
Repligen Corp COMposition key pos:13464 · issuer key iss:1834 | add | +$95.4M | +842,000 | $13.6M | $109M | 83,000 | 925,000 | |
Bicara Therapeutics Inc COMposition key sid:sec:prov:b23dd6a0ecec2737a5c87e9c74cf430d · issuer key cusip6:055477 | add | +$47.7M | +1,850,000 | $60.2M | $108M | 3,575,000 | 5,425,000 | |
Nurix Therapeutics Inc COMposition key sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf · issuer key cusip6:67080M | add | +$11.8M | +1,810,000 | $89.0M | $101M | 4,690,000 | 6,500,000 | |
Apogee Therapeutics Inc COMposition key pos:14112 · issuer key iss:217 | add | +$51.1M | +550,000 | $41.5M | $92.6M | 550,000 | 1,100,000 | |
Ascendis Pharma A/S SPONSORED ADRposition key pos:16862 · issuer key iss:252 | add | +$48.5M | +200,000 | $37.3M | $85.8M | 175,000 | 375,000 | |
Immunocore Holdings PLC ADSposition key pos:16434 · issuer key iss:1166 | add | +$63.1M | +2,181,868 | $20.3M | $83.4M | 585,000 | 2,766,868 | |
Taysha Gene Therapies Inc COM SHSposition key pos:14669 · issuer key iss:2095 | add | +$4.8M | +4,250,000 | $75.6M | $80.5M | 13,750,000 | 18,000,000 | |
Dyne Therapeutics Inc COMposition key pos:14578 · issuer key iss:778 | add | +$70.2M | +3,880,000 | $2.3M | $72.5M | 120,000 | 4,000,000 | |
Sanofi SA SPONSORED ADRposition key pos:11566 · issuer key iss:1928 | new | +$67.5M | +1,400,000 | $0 | $67.5M | — | 1,400,000 | |
BioCryst Pharmaceuticals Inc COMposition key pos:15962 · issuer key iss:374 | add | +$49.3M | +4,775,000 | $17.6M | $66.9M | 2,250,000 | 7,025,000 | |
Scholar Rock Holding Corp COMposition key pos:18628 · issuer key iss:1936 | add | +$34.3M | +624,422 | $30.8M | $65.1M | 700,000 | 1,324,422 | |
Immatics NV SHSposition key sid:sec:prov:8771e17f16590b5bd511978f2a4f7807 · issuer key cusip6:N44445 | add | −$3.6M | +50,000 | $64.3M | $60.8M | 6,125,000 | 6,175,000 | |
Bristol-Myers Squibb Co COMposition key pos:15894 · issuer key iss:435 | add | +$47.2M | +750,000 | $13.5M | $60.7M | 250,000 | 1,000,000 | |
Alcon AG ORD SHSposition key pos:18699 · issuer key iss:2659 | trim | −$26.8M | −305,000 | $87.1M | $60.3M | 1,105,000 | 800,000 | |
Monte Rosa Therapeutics Inc COMposition key sid:sec:prov:3224bd4d4c1e7dd823e99e6304f866c2 · issuer key cusip6:61225M | add | +$47.1M | +2,828,465 | $12.2M | $59.3M | 775,000 | 3,603,465 | |
Vera Therapeutics Inc CL Aposition key sid:sec:prov:c6f0567aff349dfe2dab4a6ee5ba8988 · issuer key cusip6:92337R | add | +$27.2M | +818,159 | $27.9M | $55.0M | 550,000 | 1,368,159 | |
Terns Pharmaceuticals Inc COMposition key pos:18385 · issuer key cusip6:880881 | trim | −$129M | −3,500,000 | $182M | $52.7M | 4,500,000 | 1,000,000 | |
Globus Medical Inc CL Aposition key pos:17909 · issuer key iss:1017 | trim | −$58.7M | −664,480 | $111M | $52.6M | 1,275,000 | 610,520 | |
Boston Scientific Corp COMposition key pos:14974 · issuer key iss:423 | new | +$50.2M | +800,000 | $0 | $50.2M | — | 800,000 | |
Nuvalent Inc COMposition key pos:14079 · issuer key iss:1594 | add | +$44.7M | +435,715 | $4.6M | $49.4M | 46,000 | 481,715 | |
Cogent Biosciences Inc COMposition key pos:18333 · issuer key iss:610 | new | +$47.4M | +1,230,888 | $0 | $47.4M | — | 1,230,888 | |
Alto Neuroscience Inc COM SHSposition key sid:sec:prov:d8f1dce881f876173d775baaae476159 · issuer key cusip6:02157Q | trim | +$2.2M | −420,925 | $44.2M | $46.4M | 2,485,000 | 2,064,075 | |
Rapport Therapeutics Inc COMposition key sid:sec:prov:9fd554b76cc510ac236cd887d1f06195 · issuer key cusip6:75383L | add | +$11.3M | +326,229 | $33.7M | $44.9M | 1,110,000 | 1,436,229 | |
Disc Medicine Inc COMposition key pos:13022 · issuer key iss:741 | trim | −$13.6M | −35,000 | $58.4M | $44.8M | 735,000 | 700,000 | |
United Therapeutics Corp COMposition key pos:15902 · issuer key iss:2217 | new | +$44.5M | +75,000 | $0 | $44.5M | — | 75,000 | |
Celldex Therapeutics Inc COM NEWposition key sid:sec:prov:30f8f229420c7a82ec2ecf2f2f622045 · issuer key cusip6:15117B | add | +$7.2M | +59,165 | $31.6M | $38.8M | 1,165,000 | 1,224,165 | |
KalVista Pharmaceuticals Inc COMposition key pos:10966 · issuer key cusip6:483497 | trim | +$6.7M | −40,000 | $30.5M | $37.2M | 1,890,000 | 1,850,000 | |
Xenon Pharmaceuticals Inc COMposition key pos:13384 · issuer key iss:2365 | add | +$10.3M | +39,900 | $26.9M | $37.2M | 600,000 | 639,900 | |
Solid Biosciences Inc COM NEWposition key pos:12592 · issuer key iss:2004 | trim | +$3.2M | −815,000 | $32.8M | $36.0M | 5,815,000 | 5,000,000 | |
Bright Minds Biosciences Inc COM NEWposition key sid:sec:prov:fed138ced9737b90542a54b9484d2da0 · issuer key cusip6:10919W | new | +$35.9M | +492,319 | $0 | $35.9M | — | 492,319 | |
Protagonist Therapeutics Inc COMposition key pos:14826 · issuer key iss:1773 | new | +$34.4M | +326,159 | $0 | $34.4M | — | 326,159 | |
Denali Therapeutics Inc COMposition key sid:sec:prov:8948595df4e56c28a2e8dffed59ee810 · issuer key cusip6:24823R | add | +$26.4M | +1,308,326 | $7.7M | $34.0M | 465,000 | 1,773,326 | |
Regeneron Pharmaceuticals Inc COMposition key pos:16027 · issuer key iss:1826 | new | +$30.9M | +40,000 | $0 | $30.9M | — | 40,000 | |
Waters Corp COMposition key pos:12127 · issuer key iss:2308 | new | +$29.8M | +100,000 | $0 | $29.8M | — | 100,000 | |
Viking Therapeutics Inc COMposition key pos:17730 · issuer key iss:2273 | new | +$29.7M | +914,147 | $0 | $29.7M | — | 914,147 | |
Inspire Medical Systems Inc COMposition key pos:14444 · issuer key iss:1183 | new | +$27.8M | +539,269 | $0 | $27.8M | — | 539,269 | |
Trevi Therapeutics Inc COMposition key pos:18739 · issuer key iss:2160 | new | +$25.8M | +2,166,504 | $0 | $25.8M | — | 2,166,504 | |
Soleno Therapeutics Inc COMposition key sid:sec:prov:9c654c0b85e21e330a7ebfd2ced217c7 · issuer key cusip6:834203 | new | +$24.4M | +730,000 | $0 | $24.4M | — | 730,000 | |
Beta Bionics Inc COMposition key sid:sec:prov:4e7eb09ab13c64fd6730ede8dbc988b8 · issuer key cusip6:08659B | add | +$3.9M | +1,611,518 | $18.3M | $22.2M | 600,000 | 2,211,518 | |
Nektar Therapeutics COM NEWposition key sid:sec:prov:8689270ade82a464b05b5b23e79f9006 · issuer key cusip6:640268 | new | +$20.5M | +285,000 | $0 | $20.5M | — | 285,000 | |
Cytokinetics Inc COM NEWposition key pos:13331 · issuer key iss:700 | new | +$19.8M | +300,000 | $0 | $19.8M | — | 300,000 | |
AstraZeneca PLC ORDposition key pos:18610 · issuer key iss:2433 | new | +$19.7M | +100,000 | $0 | $19.7M | — | 100,000 | |
West Pharmaceutical Services I COMposition key pos:11159 · issuer key iss:2323 | new | +$18.8M | +75,000 | $0 | $18.8M | — | 75,000 | |
GE HealthCare Technologies Inc COMMON STOCKposition key pos:17257 · issuer key iss:981 | new | +$17.8M | +250,000 | $0 | $17.8M | — | 250,000 | |
SpyGlass Pharma Inc COM SHSposition key sid:sec:prov:04667cad8d94d5f8ff4744e87dea829b · issuer key cusip6:85220G | new | +$17.3M | +666,760 | $0 | $17.3M | — | 666,760 | |
Zimmer Biomet Holdings Inc COMposition key pos:13281 · issuer key iss:2378 | add | +$3.7M | +40,000 | $13.5M | $17.2M | 150,000 | 190,000 | |
Madrigal Pharmaceuticals Inc COMposition key pos:15238 · issuer key iss:1407 | new | +$16.5M | +31,468 | $0 | $16.5M | — | 31,468 | |
GeneDx Holdings Corp COM CL Aposition key pos:11515 · issuer key iss:1951 | new | +$16.1M | +250,000 | $0 | $16.1M | — | 250,000 | |
Damora Therapeutics Inc COM NEWposition key pos:17113 · issuer key iss:983 | new | +$15.5M | +600,000 | $0 | $15.5M | — | 600,000 | |
Agios Pharmaceuticals Inc COMposition key pos:14037 · issuer key cusip6:00847X | add | +$6.4M | +125,000 | $8.8M | $15.2M | 325,000 | 450,000 | |
enGene Therapeutics Inc COMposition key sid:sec:prov:c58e51841f60c26aab31f70d6e4eabc3 · issuer key cusip6:29286M | add | +$5.2M | +1,110,000 | $9.5M | $14.7M | 1,055,000 | 2,165,000 | |
Savara Inc COMposition key sid:sec:prov:2bc6a25d40cf07124e3a03bdecf4a4df · issuer key cusip6:805111 | add | +$4.5M | +994,052 | $9.7M | $14.2M | 1,606,000 | 2,600,052 | |
Tarsus Pharmaceuticals Inc COMposition key pos:11454 · issuer key iss:2092 | new | +$14.0M | +200,000 | $0 | $14.0M | — | 200,000 | |
Voyager Therapeutics Inc COMposition key sid:sec:prov:049c2d4f45ba193716199e4b705e328c · issuer key cusip6:92915B | add | +$5.8M | +1,527,936 | $5.8M | $11.6M | 1,475,000 | 3,002,936 | |
Insulet Corp COMposition key pos:18144 · issuer key iss:1190 | new | +$10.6M | +50,601 | $0 | $10.6M | — | 50,601 | |
Surrozen Inc COM NEWposition key sid:sec:prov:0d3c6673b7060f8873ebd8344c73bee8 · issuer key cusip6:86889P | new | +$9.9M | +338,611 | $0 | $9.9M | — | 338,611 | |
Arvinas Inc COMposition key pos:12209 · issuer key iss:250 | new | +$9.6M | +905,465 | $0 | $9.6M | — | 905,465 | |
MapLight Therapeutics Inc COMposition key sid:sec:prov:25db868bd92949401541405f5298734d · issuer key cusip6:56565P | add | +$1.8M | +35,000 | $6.8M | $8.5M | 385,000 | 420,000 | |
Fulcrum Therapeutics Inc COMposition key sid:sec:prov:b66dc0816f9158ee3c706ae6f74ba1a4 · issuer key cusip6:359616 | add | −$2.3M | +150,000 | $10.7M | $8.4M | 950,000 | 1,100,000 | |
OnKure Therapeutics Inc COM CL Aposition key sid:sec:prov:1b29f8f31311ff2217960a31a2f84a8d · issuer key cusip6:68277Q | add | +$5.8M | +1,204,819 | $1.8M | $7.6M | 635,000 | 1,839,819 | |
Myriad Genetics Inc COMposition key pos:16125 · issuer key iss:1518 | add | −$105K | +425,000 | $7.5M | $7.4M | 1,223,000 | 1,648,000 | |
Olema Pharmaceuticals Inc COMposition key pos:14811 · issuer key iss:1615 | trim | −$34.9M | −1,221,449 | $41.3M | $6.4M | 1,650,000 | 428,551 | |
Anteris Technologies Global Co COMposition key sid:sec:prov:0d957017a1f6113a5600ce99517cee7f · issuer key cusip6:03675P | new | +$6.4M | +1,144,780 | $0 | $6.4M | — | 1,144,780 | |
uniQure NV SHSposition key pos:11923 · issuer key iss:2710 | new | +$5.9M | +358,996 | $0 | $5.9M | — | 358,996 | |
Candel Therapeutics Inc COMposition key sid:sec:prov:36c1cc87b96fff749fa3a87e5be52946 · issuer key cusip6:137404 | new | +$5.5M | +1,125,000 | $0 | $5.5M | — | 1,125,000 | |
Palisade Bio Inc COMposition key sid:sec:prov:fefbed769ea5db09695bd4a0f3004463 · issuer key cusip6:696389 | new | +$4.4M | +2,500,000 | $0 | $4.4M | — | 2,500,000 | |
Veracyte Inc COMposition key pos:15789 · issuer key iss:2254 | new | +$4.2M | +130,687 | $0 | $4.2M | — | 130,687 | |
Zenas Biopharma Inc COMposition key sid:sec:prov:f23e65e3d61dbc0d9c26fbeb71e72b85 · issuer key cusip6:98937L | new | +$3.9M | +200,000 | $0 | $3.9M | — | 200,000 | |
Geron Corp COMposition key sid:sec:prov:b6aaf2a1d9a7b3e3e2f1185e3325ec7d · issuer key cusip6:374163 | trim | −$11.2M | −8,780,000 | $14.9M | $3.8M | 11,320,000 | 2,540,000 | |
Monopar Therapeutics Inc COM NEWposition key sid:sec:prov:8416c67ffd3651f6a5f8d9788c0f2e31 · issuer key cusip6:61023L | new | +$3.6M | +65,418 | $0 | $3.6M | — | 65,418 | |
Zura Bio Ltd CLASS A ORD SHSposition key sid:sec:prov:37f8d7b8f8c97e91dcf78ef12d0dd5a9 · issuer key cusip6:G9TY5A | new | +$3.0M | +511,000 | $0 | $3.0M | — | 511,000 | |
Novocure Ltd ORD SHSposition key sid:sec:prov:ab3bd82b93cc9c55eaac96fb008434de · issuer key cusip6:G6674U | trim | −$4.1M | −275,000 | $6.8M | $2.7M | 525,000 | 250,000 | |
Nyxoah SA SHSposition key sid:sec:prov:20933c1bfa6479cec53caa65aff0687d · issuer key cusip6:B6S7WD | trim | −$2.6M | −238,339 | $5.1M | $2.5M | 1,107,000 | 868,661 | |
UroGen Pharma Ltd COMposition key sid:sec:prov:a469da6cabfc03832e3d85a7bff09e97 · issuer key cusip6:M96088 | new | +$2.5M | +139,079 | $0 | $2.5M | — | 139,079 | |
Tyra Biosciences Inc COMposition key sid:sec:prov:47170149b82e95e4444c881acffa67fc · issuer key cusip6:90240B | trim | −$61.7M | −2,371,000 | $63.8M | $2.1M | 2,425,000 | 54,000 | |
REGENXBIO Inc COMposition key sid:sec:prov:e7743277455b5823374498b009dffbbe · issuer key cusip6:75901B | add | +$420K | +74,525 | $490K | $909K | 34,000 | 108,525 | |
Absci Corp COMposition key sid:sec:prov:f3f8f36b088f3feb965b6e5cad32a6e3 · issuer key cusip6:00091E | new | +$697K | +232,219 | $0 | $697K | — | 232,219 | |
Aprea Therapeutics Inc COM NEWposition key sid:sec:prov:f6a724b9b2b95c7dd5f1329c4db8ca1e · issuer key cusip6:03836J | new | +$267K | +350,000 | $0 | $267K | — | 350,000 | |
| pos:11227 | exit‡e | −$15.5M | −50,000 | $15.5M | $0 | 50,000 | — | |
| pos:11444 | exit‡e | −$6.1M | −50,000 | $6.1M | $0 | 50,000 | — | |
| pos:12022 PUT | exit‡e | −$215M | −350,000 | $215M | $0 | 350,000 | — | |
| pos:12357 | exit‡e | −$5.2M | −66,000 | $5.2M | $0 | 66,000 | — | |
| pos:13229 | exit‡e | −$75.2M | −600,000 | $75.2M | $0 | 600,000 | — | |
| pos:13435 | exit‡e | −$2.1M | −870,000 | $2.1M | $0 | 870,000 | — | |
| pos:13938 | exit‡e | −$38.4M | −210,000 | $38.4M | $0 | 210,000 | — | |
| pos:14656 | exit‡e | −$24.0M | −360,000 | $24.0M | $0 | 360,000 | — | |
| pos:15540 | exit‡e | −$49.3M | −290,000 | $49.3M | $0 | 290,000 | — | |
| pos:15920 | exit‡e | −$84.6M | −1,275,000 | $84.6M | $0 | 1,275,000 | — | |
| pos:18668 | exit‡e | −$81.6M | −775,000 | $81.6M | $0 | 775,000 | — | |
| sid:sec:prov:097fe4205cdb81b5acf642533490216f | exit‡e | −$5.8M | −300,000 | $5.8M | $0 | 300,000 | — | |
| sid:sec:prov:1c7c81831d7de024bffc2474a53ee4b9 | exit‡e | −$1.2M | −755,000 | $1.2M | $0 | 755,000 | — | |
| sid:sec:prov:1e348df3cde91ba41d5ebeef0c53e107 | exit‡e | −$19.5M | −720,000 | $19.5M | $0 | 720,000 | — | |
| sid:sec:prov:3044f98940a2897deb445091c04637d0 | exit‡e | −$8.5M | −637,000 | $8.5M | $0 | 637,000 | — | |
| sid:sec:prov:37d3b7d0376e44b079f1262ff7392888 | exit‡e | −$4.4M | −275,000 | $4.4M | $0 | 275,000 | — |
80 more changes below.
1–100 of 107 changes
Mark-to-market only (no share change) · 6
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
Crescent Biopharma Inc COMposition key pos:17611 · issuer key iss:2481 | no change | +$9.8M | 0 | $17.8M | $27.6M | 1,500,000 | 1,500,000 | |
Lexeo Therapeutics Inc COMposition key sid:sec:prov:bd4b862f6cf27f7bbb6f4d26443faaca · issuer key cusip6:52886X | no change | −$18.8M | 0 | $44.4M | $25.7M | 4,475,000 | 4,475,000 | |
Tectonic Therapeutic Inc COMposition key sid:sec:prov:ab98bdc5d9f0946c8554aa4745533ba5 · issuer key cusip6:878972 | no change | +$3.3M | 0 | $6.8M | $10.1M | 328,000 | 328,000 | |
Passage Bio Inc COM NEWposition key sid:sec:prov:08f56375775bd8e0bec7962398690616 · issuer key cusip6:702712 | no change | −$1.2M | 0 | $3.6M | $2.4M | 305,000 | 305,000 | |
Tenax Therapeutics Inc COM NEWposition key sid:sec:prov:9e958f4e10d0d474cc9e75d42ea33a9a · issuer key cusip6:88032L | no change | +$203K | 0 | $651K | $854K | 53,439 | 53,439 | |
MacroGenics Inc COMposition key sid:sec:prov:2cf06ac89e78fe7c69baaccedd98a9c7 · issuer key cusip6:556099 | no change | +$358K | 0 | $451K | $809K | 280,000 | 280,000 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 67.6%below median 80.0%
- Concentration index
- 255 bpsbelow median 446 bps
- Positions with value
- 90 / 90median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 67.6% · HHI (bps) ·§: 255integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 113
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open Vestal Point Capital, LP's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–90 of 90 positions · $3.6B disclosed value over 90 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Revolution Medicines Inc Revolution Medicines Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $231M | 2,375,000 | — | 6.5% | — | |
| — | BMRNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BioMarin Pharmaceutical Inc BioMarin Pharmaceutical Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $202M | 3,575,000 | — | 5.6% | — | |
| — | ABVXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Abivax SA Abivax SA · SPONSORED ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $167M | 1,500,000 | — | 4.7% | — | |
| — | NBIXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Neurocrine Biosciences Inc Neurocrine Biosciences Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $165M | 1,250,000 | — | 4.6% | — | |
| — | — | Arrowhead Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $143M | 2,275,000 | — | 4.0% | — | |
| — | — | Enliven Therapeutics Inc Enliven Therapeutics Inc · COM CUSIP 29337E102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $127M | 3,250,000 | — | 3.6% | — | |
| — | RGENverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Repligen Corp Repligen Corp · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $109M | 925,000 | — | 3.0% | — | |
| — | — | Bicara Therapeutics Inc Bicara Therapeutics Inc · COM CUSIP 055477103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $108M | 5,425,000 | — | 3.0% | — | |
| — | — | Nurix Therapeutics Inc Nurix Therapeutics Inc · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $101M | 6,500,000 | — | 2.8% | — | |
| — | APGEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Apogee Therapeutics Inc Apogee Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $92.6M | 1,100,000 | — | 2.6% | — | |
| — | ASNDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Ascendis Pharma A/S Ascendis Pharma A/S · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $85.8M | 375,000 | — | 2.4% | — | |
| — | — | Immunocore Holdings PLC Immunocore Holdings PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $83.4M | 2,766,868 | — | 2.3% | — | |
| — | TSHAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Taysha Gene Therapies Inc Taysha Gene Therapies Inc · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $80.5M | 18,000,000 | — | 2.2% | — | |
| — | DYNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Dyne Therapeutics Inc Dyne Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $72.5M | 4,000,000 | — | 2.0% | — | |
| — | SNYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Sanofi SA Sanofi SA · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $67.5M | 1,400,000 | — | 1.9% | — | |
| — | BCRXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BioCryst Pharmaceuticals Inc BioCryst Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $66.9M | 7,025,000 | — | 1.9% | — | |
| — | — | Scholar Rock Holding Corp Scholar Rock Holding Corp · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $65.1M | 1,324,422 | — | 1.8% | — | |
| — | — | Immatics NV Immatics NV · SHS CUSIP N44445109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $60.8M | 6,175,000 | — | 1.7% | — | |
| — | BMYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Bristol-Myers Squibb Co Bristol-Myers Squibb Co · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $60.7M | 1,000,000 | — | 1.7% | — | |
| — | ALCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Alcon AG Alcon AG · ORD SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $60.3M | 800,000 | — | 1.7% | — | |
| — | — | Monte Rosa Therapeutics Inc Monte Rosa Therapeutics Inc · COM CUSIP 61225M102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $59.3M | 3,603,465 | — | 1.7% | — | |
| — | — | Vera Therapeutics Inc Vera Therapeutics Inc · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $55.0M | 1,368,159 | — | 1.5% | — | |
| — | — | Terns Pharmaceuticals Inc Terns Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $52.7M | 1,000,000 | — | 1.5% | — | |
| — | — | Globus Medical Inc Globus Medical Inc · CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $52.6M | 610,520 | — | 1.5% | — | |
| — | BSXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Boston Scientific Corp Boston Scientific Corp · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $50.2M | 800,000 | — | 1.4% | — | |
| — | NUVLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Nuvalent Inc Nuvalent Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $49.4M | 481,715 | — | 1.4% | — | |
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Cogent Biosciences Inc Cogent Biosciences Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $47.4M | 1,230,888 | — | 1.3% | — | |
| — | — | Alto Neuroscience Inc Alto Neuroscience Inc · COM SHS CUSIP 02157Q109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $46.4M | 2,064,075 | — | 1.3% | — | |
| — | — | Rapport Therapeutics Inc Rapport Therapeutics Inc · COM CUSIP 75383L102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $44.9M | 1,436,229 | — | 1.3% | — | |
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Disc Medicine Inc Disc Medicine Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $44.8M | 700,000 | — | 1.3% | — | |
| — | UTHRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | United Therapeutics Corp United Therapeutics Corp · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $44.5M | 75,000 | — | 1.2% | — | |
| — | — | Celldex Therapeutics Inc Celldex Therapeutics Inc · COM NEW CUSIP 15117B202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.8M | 1,224,165 | — | 1.1% | — | |
| — | — | KalVista Pharmaceuticals Inc KalVista Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $37.2M | 1,850,000 | — | 1.0% | — | |
| — | XENEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $37.2M | 639,900 | — | 1.0% | — | |
| — | SLDBverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Solid Biosciences Inc Solid Biosciences Inc · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $36.0M | 5,000,000 | — | 1.0% | — | |
| — | — | Bright Minds Biosciences Inc Bright Minds Biosciences Inc · COM NEW CUSIP 10919W405 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.9M | 492,319 | — | 1.0% | — | |
| — | PTGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Protagonist Therapeutics Inc Protagonist Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.4M | 326,159 | — | 1.0% | — | |
| — | — | Denali Therapeutics Inc Denali Therapeutics Inc · COM CUSIP 24823R105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.0M | 1,773,326 | — | 1.0% | — | |
| — | REGNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Regeneron Pharmaceuticals Inc Regeneron Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $30.9M | 40,000 | — | 0.9% | — | |
| — | WATverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Waters Corp Waters Corp · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $29.8M | 100,000 | — | 0.8% | — | |
| — | VKTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Viking Therapeutics Inc Viking Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $29.7M | 914,147 | — | 0.8% | — | |
| — | — | Inspire Medical Systems Inc Inspire Medical Systems Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.8M | 539,269 | — | 0.8% | — | |
| — | CBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Crescent Biopharma Inc Crescent Biopharma Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.6M | 1,500,000 | — | 0.8% | — | |
| — | TRVIverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Trevi Therapeutics Inc Trevi Therapeutics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.8M | 2,166,504 | — | 0.7% | — | |
| — | — | Lexeo Therapeutics Inc Lexeo Therapeutics Inc · COM CUSIP 52886X107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.7M | 4,475,000 | — | 0.7% | — | |
| — | — | Soleno Therapeutics Inc Soleno Therapeutics Inc · COM CUSIP 834203309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.4M | 730,000 | — | 0.7% | — | |
| — | — | Beta Bionics Inc Beta Bionics Inc · COM CUSIP 08659B102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.2M | 2,211,518 | — | 0.6% | — | |
| — | — | Nektar Therapeutics Nektar Therapeutics · COM NEW CUSIP 640268306 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.5M | 285,000 | — | 0.6% | — | |
| — | CYTKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Cytokinetics Inc Cytokinetics Inc · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.8M | 300,000 | — | 0.6% | — | |
| — | AZNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AstraZeneca PLC AstraZeneca PLC · ORD CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.7M | 100,000 | — | 0.6% | — | |
| — | — | West Pharmaceutical Services I West Pharmaceutical Services I · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.8M | 75,000 | — | 0.5% | — | |
| — | — | GE HealthCare Technologies Inc GE HealthCare Technologies Inc · COMMON STOCK CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.8M | 250,000 | — | 0.5% | — | |
| — | — | SpyGlass Pharma Inc SpyGlass Pharma Inc · COM SHS CUSIP 85220G109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.3M | 666,760 | — | 0.5% | — | |
| — | ZBHverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Zimmer Biomet Holdings Inc Zimmer Biomet Holdings Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.2M | 190,000 | — | 0.5% | — | |
| — | MDGLverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Madrigal Pharmaceuticals Inc Madrigal Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.5M | 31,468 | — | 0.5% | — | |
| — | WGSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GeneDx Holdings Corp GeneDx Holdings Corp · COM CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.1M | 250,000 | — | 0.4% | — | |
| — | DMRAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Damora Therapeutics Inc Damora Therapeutics Inc · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $15.5M | 600,000 | — | 0.4% | — | |
| — | — | Agios Pharmaceuticals Inc Agios Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $15.2M | 450,000 | — | 0.4% | — | |
| — | — | enGene Therapeutics Inc enGene Therapeutics Inc · COM CUSIP 29286M105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.7M | 2,165,000 | — | 0.4% | — | |
| — | — | Savara Inc Savara Inc · COM CUSIP 805111101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.2M | 2,600,052 | — | 0.4% | — | |
| — | TARSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Tarsus Pharmaceuticals Inc Tarsus Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.0M | 200,000 | — | 0.4% | — | |
| — | — | Voyager Therapeutics Inc Voyager Therapeutics Inc · COM CUSIP 92915B106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.6M | 3,002,936 | — | 0.3% | — | |
| — | PODDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Insulet Corp Insulet Corp · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.6M | 50,601 | — | 0.3% | — | |
| — | — | Tectonic Therapeutic Inc Tectonic Therapeutic Inc · COM CUSIP 878972108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.1M | 328,000 | — | 0.3% | — | |
| — | — | Surrozen Inc Surrozen Inc · COM NEW CUSIP 86889P208 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.9M | 338,611 | — | 0.3% | — | |
| — | ARVNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Arvinas Inc Arvinas Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.6M | 905,465 | — | 0.3% | — | |
| — | — | MapLight Therapeutics Inc MapLight Therapeutics Inc · COM CUSIP 56565P103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.5M | 420,000 | — | 0.2% | — | |
| — | — | Fulcrum Therapeutics Inc Fulcrum Therapeutics Inc · COM CUSIP 359616109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.4M | 1,100,000 | — | 0.2% | — | |
| — | — | OnKure Therapeutics Inc OnKure Therapeutics Inc · COM CL A CUSIP 68277Q105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.6M | 1,839,819 | — | 0.2% | — | |
| — | MYGNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Myriad Genetics Inc Myriad Genetics Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.4M | 1,648,000 | — | 0.2% | — | |
| — | OLMAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Olema Pharmaceuticals Inc Olema Pharmaceuticals Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.4M | 428,551 | — | 0.2% | — | |
| — | — | Anteris Technologies Global Co Anteris Technologies Global Co · COM CUSIP 03675P102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.4M | 1,144,780 | — | 0.2% | — | |
| — | QUREverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | uniQure NV uniQure NV · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.9M | 358,996 | — | 0.2% | — | |
| — | — | Candel Therapeutics Inc Candel Therapeutics Inc · COM CUSIP 137404109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.5M | 1,125,000 | — | 0.2% | — | |
| — | — | Palisade Bio Inc Palisade Bio Inc · COM CUSIP 696389402 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.4M | 2,500,000 | — | 0.1% | — | |
| — | VCYTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | Veracyte Inc Veracyte Inc · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.2M | 130,687 | — | 0.1% | — | |
| — | — | Zenas Biopharma Inc Zenas Biopharma Inc · COM CUSIP 98937L105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.9M | 200,000 | — | 0.1% | — | |
| — | — | Geron Corp Geron Corp · COM CUSIP 374163103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.8M | 2,540,000 | — | 0.1% | — | |
| — | — | Monopar Therapeutics Inc Monopar Therapeutics Inc · COM NEW CUSIP 61023L207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.6M | 65,418 | — | 0.1% | — | |
| — | — | Zura Bio Ltd Zura Bio Ltd · CLASS A ORD SHS CUSIP G9TY5A101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.0M | 511,000 | — | 0.1% | — | |
| — | — | Novocure Ltd Novocure Ltd · ORD SHS CUSIP G6674U108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.7M | 250,000 | — | 0.1% | — | |
| — | — | Nyxoah SA Nyxoah SA · SHS CUSIP B6S7WD106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.5M | 868,661 | — | 0.1% | — | |
| — | — | UroGen Pharma Ltd UroGen Pharma Ltd · COM CUSIP M96088105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.5M | 139,079 | — | 0.1% | — | |
| — | — | Passage Bio Inc Passage Bio Inc · COM NEW CUSIP 702712209 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.4M | 305,000 | — | 0.1% | — | |
| — | — | Tyra Biosciences Inc Tyra Biosciences Inc · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.1M | 54,000 | — | 0.1% | — | |
| — | — | REGENXBIO Inc REGENXBIO Inc · COM CUSIP 75901B107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $909K | 108,525 | — | 0.0% | — | |
| — | — | Tenax Therapeutics Inc Tenax Therapeutics Inc · COM NEW CUSIP 88032L605 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $854K | 53,439 | — | 0.0% | — | |
| — | — | MacroGenics Inc MacroGenics Inc · COM CUSIP 556099109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $809K | 280,000 | — | 0.0% | — | |
| — | — | Absci Corp Absci Corp · COM CUSIP 00091E109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $697K | 232,219 | — | 0.0% | — | |
| — | — | Aprea Therapeutics Inc Aprea Therapeutics Inc · COM NEW CUSIP 03836J201 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $267K | 350,000 | — | 0.0% | — |
1–90 of 90 positions · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).